The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial
Open accessAbstract
BACKGROUND: No therapies have been proven to persistently improve the outcome of HTLV-I-associated myelopathy. Clinical benefit has been reported with zidovudine and with lamivudine in observational studies. We therefore conducted a randomised, double blind, placebo controlled study of six months combination therapy with these nucleoside analogues in sixteen patients. RESULTS: Primary outcomes were change in HTLV-I proviral load in PBMCs and clinical measures. Secondary endpoints were changes in T-cell subsets and markers of activation and proliferation. Six patients discontinued zidovudine. No significant changes in pain, bladder function, disability score, gait, proviral load or markers of T-cell activation or proliferation were seen between the two arms. Active therapy was associated with an unexplained decrease in CD8 and non-T lymphocyte counts. CONCLUSION: Failure to detect clinical improvement may have been due irreversible nerve damage in these patients with a long clinical history and future studies should target patients presenting earlier. The lack of virological effect but may reflect a lack of activity of these nucleoside analogues against HTLV-I RT in vivo, inadequate intracellular concentrations of the active moiety or the contribution of new cell infection to maintaining proviral load at this stage of infection may be relatively small masking the effects of RT inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“yet, contrary to the HIV field, such success has not been imitated in the treatment of HTLV-1 [159,160,161].”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [161]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ANTIBODIES TO HUMAN T-LYMPHOTROPIC VIRUS TYPE-I IN PATIENTS WITH TROPICAL SPASTIC PARAPARESIS
Gessain, A., Vernant, J. C., Maurs, L., Barin, F., Gout, O., Calender, A., & de Thé, G. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92734-5 · Cited by 2,812
HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITY
Osame, M., Usuku, K., Izumo, S., Ijichi, N., Amitani, H., Igata, A., Matsumoto, M., & Tara, M. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91298-5 · Cited by 2,381
Self-citation李燕娜 (2016) · Japanese journal of leprosy · doi:10.5025/hansen.85.157 · Cited by 1,359
Spread of HTLV-I Between Lymphocytes by Virus-Induced Polarization of the Cytoskeleton
Igakura, T., Stinchcombe, J. C., Goon, P. K. C., Taylor, G. P., Weber, J. N., Griffiths, G. M., Tanaka, Y., Osame, M., & Bangham, C. R. M. (2003) · Science · doi:10.1126/science.1080115 · Cited by 755
Self-citationNagai, M., Usuku, K., Matsumoto, W., Kodama, D., Takenouchi, N., Moritoyo, T., Hashiguchi, S., Ichinose, M., Bangham, C. R., Izumo, S., et al. (1998) · Journal of Neurovirology · doi:10.3109/13550289809114225 · Cited by 694
Self-citationKaplan, J. E., Osame, M., Kubota, H., Igata, A., Nishitani, H., Maeda, Y., KHABBAZ, R. F., & Janssen, R. S. (1990) · PubMed · Cited by 369
Self-citationGreten, T. F., Slansky, J. E., Kubota, R., Soldan, S. S., Jaffee, E. M., Leist, T. P., Pardoll, D. M., Jacobson, S., & Schneck, J. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7568 · Cited by 247
Discovery of adult T-cell leukemia
Takatsuki, K. (2005) · Retrovirology · doi:10.1186/1742-4690-2-16 · Cited by 222
The discovery of the first human retrovirus: HTLV-1 and HTLV-2
Gallo, R. C. (2005) · Retrovirology · doi:10.1186/1742-4690-2-17 · Cited by 200
Increased replication of HTLV‐I in HTLV‐I–associated myelopathy
Yoshida, M., Osame, M., Kawai, H., Toita, M., Kuwasaki, N., Nishida, Y., Hiraki, Y., Takahashi, K., Nomura, K., Sonoda, S., et al. (1989) · Annals of Neurology · doi:10.1002/ana.410260304 · Cited by 176
Self-citation
Cited by
Sorted by citations
Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation
Matsuoka, M., & Jeang, K.-T. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2111 · Cited by 829
Human T-lymphotropic virus 1: recent knowledge about an ancient infection
Verdonck, K., González, E., Van Dooren, S., Vandamme, A.-M., Vanham, G., & Gotuzzo, E. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70081-6 · Cited by 661
Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases
Gonçalves, D. U., Proietti, F. A., Ribas, J. G. R., Araújo, M. G., Pinheiro, S. R., Guedes, A. C., & Carneiro-Proietti, A. B. F. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00063-09 · Cited by 478
Gillet, N. A., Florins, A., Boxus, M., Burteau, C., Nigro, A., Vandermeers, F., Balon, H., Bouzar, A., Defoiche, J., Burny, A., et al. (2007) · Retrovirology · doi:10.1186/1742-4690-4-18 · Cited by 400
HTLV-1-associated myelopathy/tropical spastic paraparesis
Bangham, C. R. M., Araújo, A., Yamano, Y., & Taylor, G. P. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.12 · Cited by 283
Self-citation
Metadata
- Authors
- Taylor, G. P., Goon, P., Furukawa, Y., Green, H., Barfield, A., Mosley, A., Nose, H., Babiker, A., Rudge, P., Usuku, K., Osame, M., Bangham, C. R., & Weber, J. N.
- Affiliations
- Imperial College London (GB)
- Kagoshima University (JP)
- Medical Research Council (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- Corresponding author
- Taylor, Graham P
- Venue
- Retrovirology
- Published
- 2006-09-19
- Volume
- 3
- Issue
- 1
- Pages
- 63-63
- ISSN
- 1742-4690 (ISSN-L)
- PMC
- PMC1590049
- OpenAlex
- W2154664865
- Cited by
- 117
- References
- 35
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 4 · 2022: 1 · 2021: 2 · 2020: 8 · 2019: 8 · 2018: 6 · 2017: 5 · 2016: 9 · 2015: 11 · 2014: 8 · 2013: 10 · 2012: 6
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Retrovirology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by)
- Funders
- GlaxoSmithKline
- Medical Research Council
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- tropical spastic paraparesis, zidovudine, lamivudine, nucleoside reverse transcriptase inhibitors, highly active antiretroviral therapy, T cell activation, CD8+ T cell depletion, treatment discontinuation, nerve injury
- MeSH terms
- Aged, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Placebos, Zidovudine, Paraparesis, Tropical Spastic, Lamivudine, Anti-HIV Agents, Viral Load, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
